Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, develops and commercializes medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, oral formulation of oxycodone; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol; and Xtampza ER for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment. The company was formerly known as Collegium Pharmaceuticals, Inc. and changed its name to Collegium Pharmaceutical, Inc. in October 2003. Collegium Pharmaceutical, Inc. was incorporated in 2002 and is headquartered in Stoughton, Massachusetts.

Mr. Bart J. Dunn

Executive Vice President of Strategy & Corporate Development

Mr. Michael Thomas Heffernan B.S. Pharm, R.Ph.

Co-Founder & Independent Chairman

Ms. Colleen  Tupper

Executive Vice President & Chief Financial Officer

Mr. Scott  Dreyer

Executive Vice President & Chief Commercial Officer

Mr. Joseph J. Ciaffoni

President, Chief Executive Officer & Director

Dr. Thomas B. Smith FAAFP, M.D.

Executive Vice President & Chief Medical Officer

Mr. Scott  Sudduth

Head of Technical Operations

Ms. Shirley R. Kuhlmann

Executive Vice President, General Counsel, Chief Administrative Officer & Secretary

Dr. Christopher Shayne James M.D.

Vice President of Investor Relations

Collegium Pharmaceutical, Inc.

Collegium Pharmaceutical, Inc. Management-Struktur

Informationen zum Management